Novo Nordisk launches Ozempic and Fiasp, expanding treatment options for adults with diabetes. Novo Nordisk on Monday announced the availability of two new diabetes medications, Ozempic (semaglutide) injection 0.5 mg or 1 mg and Fiasp (insulin aspart injection) 100 Units/mL at pharmacies across the United States. Ozempic is a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an…